For further details see:
Eli Lilly, Magnite leads the premarket losers' packFor further details see:
Eli Lilly, Magnite leads the premarket losers' packMarket Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
2024-07-05 06:22:00 ET Eli Lilly (NYSE: LLY) has become a big name in the anti-obesity market with the recent approval of Zepbound, which is likely to rake in billions in revenue alongside Mounjaro, the company's diabetes treatment. Year to date, the stock is already up 57% as inves...
2024-07-04 07:30:00 ET Eli Lilly (NYSE: LLY) is emerging as arguably the top stock in the anti-obesity market. It has a couple of fantastic products in Zepbound, which is approved for weight loss, and Mounjaro, which is essentially the same thing but is approved to treat diabetes. B...
2024-07-04 05:50:00 ET A few years ago, Eli Lilly (NYSE: LLY) was far from the hottest stock in the biopharmaceutical world. But times have changed. Today, Lilly ranks as the biggest healthcare company in the world. It still has tremendous growth prospects with its diabetes, obesity...